Evidence map›Paper›PMID 22615931›Full record

ArticlePloS one2012

Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission.

James A Gregory, Fengwu Li, Lauren M Tomosada, Chesa J Cox, Aaron B Topol, Joseph M Vinetz, Stephen Mayfield

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 138 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Molecules (Basel, Switzerland) · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Efforts to Develop Pfs25 Vaccines.The American journal of tropical medicine and hygiene · 2022
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. A review on edible vaccines and their prospects.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

James A GregoryDivision of Biological Sciences, and the San Diego Center for Algae Biotechnology, University of California San Diego, California, United States of America.
Fengwu Li
Lauren M Tomosada
Chesa J Cox
Aaron B Topol
Joseph M Vinetz
Stephen Mayfield
University of California, San Diego · US

Funding

MOLECULAR TARGETS OF BLOCKING MALARIA TRANSMISSIONR01AI045999 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI VINETZ, JOSEPH M. · 2000 to 2010
$3.2M
Patient-Oriented Research in Tropical Infectious DiseasesK24AI068903 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VINETZ, JOSEPH M. · 2006 to 2015
$1.5M
NIAID NIH HHS AI45999NIAID NIH HHS R01 AI045999
6 · The paper itself

Abstract

Subunit vaccines are significantly more expensive to produce than traditional vaccines because they are based primarily on recombinant proteins that must be purified from the expression system. Despite the increased cost, subunit vaccines are being developed because they are safe, effective, and can elicit antibodies that confer protection against diseases that are not currently vaccine-preventable. Algae are an attractive platform for producing subunit vaccines because they are relatively inexpensive to grow, genetically tractable, easily scaled to large volumes, have a short generation time, and are devoid of inflammatory, viral, or prion contaminants often present in other systems. We tested whether algal chloroplasts can produce malaria transmission blocking vaccine candidates, Plasmodium falciparum surface protein 25 (Pfs25) and 28 (Pfs28). Antibodies that recognize Pfs25 and Pfs28 disrupt the sexual development of parasites within the mosquito midgut, thus preventing transmission of malaria from one human host to the next. These proteins have been difficult to produce in traditional recombinant systems because they contain tandem repeats of structurally complex epidermal growth factor-like domains, which cannot be produced in bacterial systems, and because they are not glycosylated, so they must be modified for production in eukaryotic systems. Production in algal chloroplasts avoids these issues because chloroplasts can fold complex eukaryotic proteins and do not glycosylate proteins. Here we demonstrate that algae are the first recombinant system to successfully produce an unmodified and aglycosylated version of Pfs25 or Pfs28. These antigens are structurally similar to the native proteins and antibodies raised to these recombinant proteins recognize Pfs25 and Pfs28 from P. falciparum. Furthermore, antibodies to algae-produced Pfs25 bind the surface of in-vitro cultured P. falciparum sexual stage parasites and exhibit transmission blocking activity. Thus, algae are promising organisms for producing cysteine-disulfide-containing malaria transmission blocking vaccine candidate proteins.

Indexed as

Amino Acid SequenceAnimalsAntigens, ProtozoanChlamydomonas reinhardtiiChloroplastsMalaria, FalciparumMalaria VaccinesPlasmodium falciparumProtozoan ProteinsAntigens, ProtozoanMalaria VaccinesPfs25 protein, Plasmodium falciparumProtozoan Proteins

Identifiers

PMID22615931
PMCPMC3353897
OpenAlexW1973771056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.